Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure

P. Mammen, Mammen; Tebas, Pablo; Agnes, Joseph; Giffear, Mary; A. Kraynyak, Kimberly; Blackwood, Elliott; Amante, Dinah; L. Reuschel, Emma; Purwar, Mansi; Christensen-Quick, Aaron; Liu, Nieman; M. Andrade, Viviane; Carter, Julie; Garufi, Gabriella; Diehl, Malissa; J. Sylvester, Albert; P. Morrow, Matthew; Pezzoli, Patrick; J. Kulkarni, Abhijeet; I. Zaidi, Faraz; Frase, Drew; Liaw, Kevin; Badie, Hedieh; O. Simon, Keiko; R.F. Smith, Trevor; Ramos, Stephanie; W. Spitz, Robert; J. Juba, Robert; Lee, Jessica; Dallas, Michael; Shah Brown, Ami; E. Shea, Jacqueline; Joseph Kim, J.; B. Weiner, David; E. Broderick, Kate; Boyer, Jean; Humeau, Laurent

doi:10.1101/2021.05.07.21256652

Public

Safety and immunogenicity of INO-4800 DNA vaccine against SARS-CoV-2: a preliminary report of a randomized, blinded, placebo-controlled, Phase 2 clinical trial in adults at high risk of viral exposure

Shared by NobleBlocks on May 7, 2021 • 12:00 AM UTC

Authors:

Mammen P. Mammen

Pablo Tebas

Joseph Agnes

Abstract

Abstract Background Vaccines against SARS-CoV-2 are still urgently needed as only 5% of the global population has been vaccinated. Here we report the safety and immunogenicity of a DNA vaccine (INO-4800) targeting the full-length Spike antigen of SARS-CoV-2 when given to adults at high-risk of expos...

Subject

Medicine

Immunogenicity

Adverse effect

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!